CD8A and graft versus host disease: Goodyear et al. (155) showed that azacitidine (AZA) both augmented the expansion of regulatory T cells and induced cytotoxic CD8+ T-cell responses to several tumor antigens, and leading to hopes that it might facilitate successful cultivation of the GVL response without inducing significant GVHD.